Sakai Akihiro, Hotomi Muneki, Billal Dewan S, Yamauchi Kazuma, Shimada Jun, Tamura Shinji, Fujihara Keiji, Yamanaka Noboru
Department of Otolaryngology--Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan.
Acta Otolaryngol. 2005 Feb;125(2):180-3. doi: 10.1080/00016480410020301.
Younger children tend to harbor more resistant strains because they are exposed to these pathogens more often through contacts with siblings or attendance at day-care centers and are frequently treated with antibiotics. The high prevalence of BLNAR strains should be taken into account in the treatment of AOM in young children.
Non-beta-lactamase-producing ampicillin-resistant (BLNAR) strains with mutations in penicillin-binding protein (PBP) genes of Haemophilus influenzae have been prevalent recently among younger children.
We investigated mutations in the ftsI gene encoding PBP-3 of H. influenzae isolated from the nasopharynx of children with acute otitis media (AOM) using polymerase chain reaction (PCR).
Strains containing the bla gene (beta-lactamase-producing ampicillin-resistant) were identified in 4.7% of cases. Strains with mutations in the ftsI gene (BLNAR) were identified in 23.3% of cases. Strains without mutations in the ftsI gene and that did not contain the bla gene (non-beta-lactamase-producing ampicillin-susceptible) were identified in 70.7% of cases. Strains with both expression of the bla gene and mutations in the ftsI gene (beta-lactamase-producing amoxicillin clavulanate-resistant) were identified in 1.3% of cases. The MICs of ampicillin against the strains evaluated in this study were 0.5-2.0 microg/ml. Cefditoren-pivoxil had the lowest MIC90 against the strains (0.06 microg/ml). Strains with mutations in the ftsI gene (BLNAR) were broadly identified among young children.
年幼儿童往往携带更多耐药菌株,因为他们通过与兄弟姐妹接触或上日托中心更频繁地接触这些病原体,并且经常接受抗生素治疗。在治疗年幼儿童的急性中耳炎(AOM)时,应考虑到产β-内酰胺酶的氨苄西林耐药(BLNAR)菌株的高流行率。
最近,在年幼儿童中,青霉素结合蛋白(PBP)基因突变的非产β-内酰胺酶氨苄西林耐药(BLNAR)流感嗜血杆菌菌株很普遍。
我们使用聚合酶链反应(PCR)研究了从急性中耳炎(AOM)患儿鼻咽部分离出的流感嗜血杆菌中编码PBP-3的ftsI基因突变情况。
在4.7%的病例中鉴定出含有bla基因(产β-内酰胺酶的氨苄西林耐药)的菌株。在23.3%的病例中鉴定出ftsI基因突变的菌株(BLNAR)。在70.7%的病例中鉴定出ftsI基因无突变且不含有bla基因的菌株(非产β-内酰胺酶的氨苄西林敏感)。在1.3%的病例中鉴定出同时表达bla基因和ftsI基因突变的菌株(产β-内酰胺酶的阿莫西林克拉维酸耐药)。本研究中评估的菌株对氨苄西林的最低抑菌浓度(MIC)为0.5-2.0微克/毫升。头孢妥仑匹酯对这些菌株的MIC90最低(0.06微克/毫升)。ftsI基因突变的菌株(BLNAR)在年幼儿童中广泛存在。